Patients taking Kerendia saw significant reduction in cardiovascular death and hospitalization and urgent visits for heart ...

Following priority review, the U.S. Food and Drug Administration approved Bayer's Kerendia (finerenone) for the treatment of ...

The FDA expanded the indication for finerenone (Kerendia) in heart failure (HF), drug manufacturer Bayer announced.

The approval was supported by data from the randomized, double-blind, placebo-controlled, event-driven phase 3 FINEARTS-HF study.

Tempus AI, Inc. (NASDAQ:TEM) saw its stock rise 3% on Wednesday following the announcement that the company obtained 510(k) ...

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care ...

The US regulator has cleared use of Kerendia (finerenone) for the treatment of heart failure patients who have a left ...

An artificial intelligence model developed by Mayo Clinic and Ultromics accurately screens for cardiac amyloidosis using a ...

The use of SGLT2 inhibitors has been a game-changer in the treatment of heart failure (HF). Now, another drug class has ...

Patients with overweight or obesity and heart failure with preserved ejection fraction that have unintentional weight loss have worse outcomes.

Part 3: Heart Failure With Reduced Ejection Fraction: Diagnosis and Evaluation. Part 4: Case Study: Lightheadedness, Fatigue in Man With Hypertension. Up next: Medical Management ...

While heart failure overall is decreasing in age-specific incidence, the trends diverge by ejection fraction. For example, in a study from the Minnesota county near the Mayo Clinic, age- and sex ...